Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 16INDUSTRY 6NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Endocrine 2Thoracic 1NET 1CNS 1Breast 1

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1Colonic Neoplasms 1Anus Neoplasms 1

Interventions

Fluorouracil 74Leucovorin 48Oxaliplatin 44Cisplatin 40Capecitabine 39Gemcitabine 37Radiotherapy 30Irinotecan 28Cetuximab 21Paclitaxel 15Bevacizumab 12Docetaxel 10Taxes 9durvalumab 8dehydroftorafur 8Surgical Procedures, Operative 8Mitomycin 8Specimen Handling 7Platinum 7Folfox protocol 7Carboplatin 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7S 1 (combination) 6Panitumumab 6Watchful Waiting 5Imatinib Mesylate 5Gene Expression Profiling 5Epirubicin 5tremelimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Octreotide × Gastrointestinal × Clear all
NCT00003057 2023-06-18

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
500 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

NCT00075868 2015-11-17

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
233 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡